Veradermics Raises $75 Million in Series B Financing; Initiates Phase 2/3 Trial for Hair Loss
Veradermics closed a $75 million Series B financing which will be used to fund the ongoing pivotal clinical development of VDPHL01 for the treatment of androgenetic alopecia (AGA). VDPHL01 is a non-hormonal oral therapeutic. The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA. The trial will enroll approximately […]